Modified Deep Extubation vs. Standard Awake Extubation
Launched by SAMUEL LUNENFELD RESEARCH INSTITUTE, MOUNT SINAI HOSPITAL · Mar 15, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is comparing two methods of safely waking patients up from anesthesia after laparoscopic surgery: a modified deep extubation (mDE) and a standard awake extubation (AE). The modified deep extubation allows patients to remain slightly under anesthesia with a lower dose of gas, which may help them recover more quickly. Researchers believe that using the modified technique could reduce the time it takes for patients to be ready to leave the operating room by at least 5 minutes compared to the standard method.
To participate in this trial, patients must be ASA physical status I-III, meaning they are generally healthy to moderately ill, and are undergoing laparoscopic surgery under general anesthesia. However, those with specific high-risk factors, such as a difficult airway history or being pregnant, will not be eligible. Participants can expect careful monitoring throughout the process, and the study aims to improve recovery experiences for patients undergoing similar surgeries in the future. If you're considering joining the trial, it could be a great opportunity to contribute to advancements in anesthesia care.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • ASA I-III
- • laparoscopic surgery under general anesthesia
- Exclusion Criteria:
- * High-risk patients:
- • Documented difficult airway during intubation or developed intraoperatively.
- • Full stomach
- • Pregnant women
- • Emergency surgery
- • BMI\>30
- • Intraoperative bleeding leading to transfusion
- • Use of remifentanil during extubation
- • Requirement for prone position for surgical approach (i.e., spine surgery, anal fistulectomy, tumor resection of the back, etc)
- • Absolute indication for awake or deep extubation
- • Use of opioids in chronic pain patients
About Samuel Lunenfeld Research Institute, Mount Sinai Hospital
The Samuel Lunenfeld Research Institute at Mount Sinai Hospital is a leading biomedical research facility dedicated to advancing our understanding of human health and disease. Renowned for its innovative research programs, the institute focuses on areas such as cancer, genetics, and reproductive health, fostering collaboration among top-tier scientists and clinicians. With a commitment to translating research findings into clinical applications, the Samuel Lunenfeld Research Institute plays a pivotal role in the development of novel therapies and interventions, thereby contributing to improved patient outcomes and the advancement of medical science.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Toronto, Ontario, Canada
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported